Marijuana stocks have been fueled by volatility and speculation ever since the words “medical marijuana” and “stocks” were used in the same sentence. When marijuana became legal for recreational use in 2014 in the state of Colorado, there was a whole new world of opportunity for both entrepreneurs and for investors. Though many of these marijuana stocks are penny stocks the same ideology holds true as traditional stock investing and many are finding opportunity for profits in this growing space. Micro-economies are blooming as well and you can find companies within the marijuana industry which focus on anything from biotechnology similar to those of Insys Therapeutics Inc
(NASDAQ:INSY) and GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), to lifestyle beverages infused with cannabis or hemp just like what FBEC Worldwide Inc (OTCMKTS:FBEC) has started to develop and bring to market.
GW Pharmaceuticals PLC- ADR reported earlier this month that it has begun to undertake the second of two Phase 3 trials of their Epidiolex(R), administered for therapies concerning Lennox-Gastaut syndrome. This is a unique and debilitating form of “childhood-onset epilepsy”.
GW received Orphan Drug Designation from the U.S. FDA in 2014 for the drug and its treatment of LGS. Initial data from these trials are expected to be released during the first quarter of 2016. Since early April, the share price for GWPH has been on a consistent uptrend. The stock has moved up from lows of $89.65 to highs of $128.25 earlier in June & currently trading around $120 per share
Insys Therapeutics Inc has also focused on cannabinoid therapy. They develop novel drugs and delivery methods using methods such as sublingual sprays. The company’s two main products include Subsys®, a sublingual Fentanyl spray to help with cancer pain and a generic version of Dronabinol capsules or THC capsules. On June 17 the Company announced that its CEO, Michael Babich and its CFO, Darryl Baker will be presenting at an upcoming conference, the JMP Securities Life Sciences Conference 2015 held at the St. Regis Hotel in New York City on June 24. A recently submitted “New Drug Application” to the FDA for a Dronabinol Oral Solution has the company and investors reacting favorably to an anticipated success as a more effective option compared to a soft gel capsule.
On the lighter side of the marijuana industry, there are still many who would like to take advantage of the biologic effects of the cannabis plant without the need for a prescription. In this case, the cannabis marketplace has begun to see a rise in infused products including hemp infused beverages. FBEC Worldwide has begun to develop a suit of these products, which take advantage of a super food like Hemp. The company has engaged California-based J&D Labs, Inc. in aiding the company with its processes to manufacture hemp-based nutraceuticals. Over recent weeks, the stock has enjoyed a health uptrend moving from $0.0456 at the beginning of June to highs of $0.12 last week (June 10)